Brind.

Comparison of 4D Molecular Therapeutics and GeoVax Labs Valuation and Risk

1 report, 1 independent Updated Oct 24
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

4D Molecular Therapeutics and GeoVax Labs are both classified as small-cap healthcare companies. A comparison of the two firms showed that 4D Molecular Therapeutics has a consensus target price of $28.90, while GeoVax Labs has a consensus target price of $150.00. Analysts noted that GeoVax Labs is considered more favorable due to its higher probable upside.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights significant differences in risk and market perception between the two companies. 4D Molecular Therapeutics has a beta of 2.75, while GeoVax Labs has a beta of 3.69, indicating higher volatility for GeoVax Labs. Furthermore, 99.3% of 4D Molecular Therapeutics shares are held by institutional investors, compared to 6.1% for GeoVax Labs.

From themarketsdaily.com

Coverage

Newest first; wire copies grouped